ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 503,27
-2,66%
Dow Jones
38 589,16
-0,15%
DAX
18 002,02
-1,43%
Brent Oil
82,275
0,00%
Bitcoin
66 191,94
0,28%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Silverback Therapeutics Inc (SBTX)

  7. Silverback Therapeutics Inc (SBTX) Actualités

SBTX

Silverback Therapeutics (SBTX)

Silverback Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:SBTX
DateHeureSourceTitreSymboleSociété
28/06/202322h32Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SBTXSilverback Therapeutics Inc
15/05/202315h08Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:SBTXSilverback Therapeutics Inc
08/05/202322h35Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:SBTXSilverback Therapeutics Inc
01/05/202322h42Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:SBTXSilverback Therapeutics Inc
01/05/202322h31Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:SBTXSilverback Therapeutics Inc
23/03/202321h14Edgar (US Regulatory)Annual Report (10-k)NASDAQ:SBTXSilverback Therapeutics Inc
23/02/202322h01GlobeNewswire Inc.ARS Pharmaceuticals Announces Presentation of Data Supporting neffy (epinephrine nasal spray) and Real-World Burden of Needle InjectorsNASDAQ:SBTXSilverback Therapeutics Inc
22/02/202322h05GlobeNewswire Inc.ARS Pharmaceuticals Reacquires European Marketing Rights to neffy® (ARS-1) for the Treatment of Type I Allergic Reactions Including AnaphylaxisNASDAQ:SBTXSilverback Therapeutics Inc
13/02/202322h33Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:SBTXSilverback Therapeutics Inc
09/02/202312h30GlobeNewswire Inc.ARS Pharmaceuticals to Participate in the SVB Securities Virtual Global Biopharma Conference 2023NASDAQ:SBTXSilverback Therapeutics Inc
17/01/202323h07Edgar (US Regulatory)Amended Current Report Filing (8-k/a)NASDAQ:SBTXSilverback Therapeutics Inc
17/01/202322h31Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:SBTXSilverback Therapeutics Inc
05/01/202323h02Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SBTXSilverback Therapeutics Inc
30/11/202222h24Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:SBTXSilverback Therapeutics Inc
21/11/202222h08Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:SBTXSilverback Therapeutics Inc
10/11/202223h02Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:SBTXSilverback Therapeutics Inc
10/11/202214h00GlobeNewswire Inc.ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including AnaphylaxisNASDAQ:SBTXSilverback Therapeutics Inc
08/11/202222h02GlobeNewswire Inc.ARS Pharmaceuticals Closes Merger with Silverback TherapeuticsNASDAQ:SBTXSilverback Therapeutics Inc
27/10/202222h17Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:SBTXSilverback Therapeutics Inc
21/10/202214h36Dow Jones NewsSilverback Therapeutics' Nasal Spray for Allergic Reactions Gets FDA Review ApprovalNASDAQ:SBTXSilverback Therapeutics Inc
21/10/202213h31Business WireSilverback Therapeutics, Inc. announces the FDA’s acceptance of ARS Pharmaceuticals’ NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including AnaphylaxisNASDAQ:SBTXSilverback Therapeutics Inc
06/10/202222h17Edgar (US Regulatory)Proxy Statement - Merger or Acquisition (definitive) (defm14a)NASDAQ:SBTXSilverback Therapeutics Inc
11/08/202223h23Edgar (US Regulatory)Proxy Statement - Merger or Acquisition (preliminary) (prem14a)NASDAQ:SBTXSilverback Therapeutics Inc
22/07/202212h15TipRanksAnalysts Offer Insights on Healthcare Companies: Plus Therapeutics (PSTV), Anixa Biosciences (ANIX) and Silverback Therapeutics (SBTX)NASDAQ:SBTXSilverback Therapeutics Inc
21/07/202222h00Business WireSilverback Therapeutics and ARS Pharmaceuticals Announce MergerNASDAQ:SBTXSilverback Therapeutics Inc
18/07/202212h01Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:SBTXSilverback Therapeutics Inc
17/05/202222h05Business WireSilverback Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment ConferenceNASDAQ:SBTXSilverback Therapeutics Inc
15/05/202218h38TipRanksJonesTrading Keeps Their Hold Rating on Silverback Therapeutics (SBTX)NASDAQ:SBTXSilverback Therapeutics Inc
13/05/202214h49TipRanksH.C. Wainwright Keeps a Hold Rating on Silverback Therapeutics (SBTX)NASDAQ:SBTXSilverback Therapeutics Inc
12/05/202222h01Business WireSilverback Therapeutics Reports First Quarter 2022 Financial Results and Provides Business UpdateNASDAQ:SBTXSilverback Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:SBTX

Dernières Valeurs Consultées

EU
BN
Danone
NASDAQ
AAPL
Apple
EU
BNP
BNP Paribas
EU
CS
Axa
NASDAQ
AMZN
Amazon.com
EU
ML
Michelin
EU
ACA
Credit Agricole
EU
VK
Vallourec
USI
USTECH100
US Tech 100
COIN
BTCUSD
Bitcoin
NYSE
KO
Coca Cola
EU
VIV
Vivendi
SPI
SP500
S&P 500
NYSE
MCD
McDonalds
EU
RI
Pernod Ricard
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés